Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INDOMETHACIN SODIUM vs VIMOVO
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, antipyretic, and analgesic effects.
VIMOVO (esomeprazole and naproxen) is a fixed-dose combination. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, thereby reducing inflammation, pain, and fever. Esomeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase in gastric parietal cells. The combination is intended to reduce the risk of NSAID-associated gastric ulcers.
Moderate to severe rheumatoid arthritis including acute flares,Ankylosing spondylitis,Osteoarthritis,Acute gouty arthritis,Patent ductus arteriosus closure (neonates),Off-label: Pericarditis (prevention of postpericardiotomy syndrome)
Relief of signs and symptoms of osteoarthritis,Relief of signs and symptoms of rheumatoid arthritis,Relief of signs and symptoms of ankylosing spondylitis,Decreased risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers
Intravenous: 0.5 mg/kg every 12 hours or 0.25 mg/kg every 6 hours for patent ductus arteriosus closure in neonates. Oral/immediate-release: 25-50 mg two to three times daily. Extended-release: 75 mg once daily or 75 mg twice daily. Maximum daily dose: 200 mg.
One tablet (naproxen 500 mg/esomeprazole 20 mg) orally twice daily.
Terminal elimination half-life: 4.5 hours (range 2.6–11.2 hours); half-life may be prolonged in neonates, elderly, and renal impairment
Naproxen: 12-17 hours (prolonged in elderly and renal impairment; dosing interval typically 12 hours). Esomeprazole: 1-1.5 hours (metabolized by CYP2C19 and CYP3A4; no accumulation after repeated dosing).
Hepatic metabolism via O-demethylation, N-deacylation, and glucuronidation; minor oxidation. CYP450 involvement is limited; primarily via UGT (glucuronidation).
GFR 30-60 m L/min: No adjustment needed. GFR 15-29 m L/min: Consider dose reduction by 25-50% or extended dosing interval. GFR <15 m L/min: Avoid use or use with extreme caution; maximum dose 100 mg/day if necessary.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: contraindicated.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Indomethacin is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
FDA Pregnancy Category C (first and second trimester) and Category D (third trimester). Indomethacin crosses the placenta. First trimester: Possible increased risk of cardiac defects (case-control studies show OR 1.5-2.0 for cardiovascular malformations). Second trimester: Avoid prolonged use due to risk of oligohydramnios. Third trimester: Contraindicated after 30-32 weeks gestation due to risk of premature closure of the ductus arteriosus (increases with gestational age), oligohydramnios, and neonatal complications (pulmonary hypertension, renal dysfunction).
Pregnancy Category C (first and second trimesters) and Category D (third trimester). First trimester: NSAIDs are associated with increased risk of miscarriage and cardiac defects; esomeprazole has no consistent evidence of major malformations. Second trimester: NSAIDs may cause fetal renal dysfunction and oligohydramnios; esomeprazole risk remains low. Third trimester: NSAIDs cause premature closure of ductus arteriosus and potential persistent pulmonary hypertension; esomeprazole risks are minimal.
Indomethacin sodium is highly effective for acute gout but carries significant GI and renal risks. Use lowest effective dose for shortest duration. Monitor renal function and electrolytes, especially in elderly or dehydrated patients. Can cause headache, dizziness, and confusion; caution in patients with history of seizures or psychiatric disorders. Avoid concurrent use with other NSAIDs, anticoagulants, and lithium. In neonates, indomethacin is used to close patent ductus arteriosus, but monitor for oliguria and platelet dysfunction.
VIMOVO is a fixed-dose combination of naproxen (NSAID) and esomeprazole (PPI). Used for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk for NSAID-associated gastric ulcers. Administer at least 30 minutes before meals. Not interchangeable with naproxen plus esomeprazole separate products. Avoid with aspirin or other NSAIDs. Monitor renal function, blood pressure, and signs of GI bleeding. Contraindicated in severe heart failure, active GI bleed, or history of aspirin/NSAID allergy.
No interactions on record
No interactions on record
INDOMETHACIN SODIUM and VIMOVO are distinct pharmacological agents. INDOMETHACIN SODIUM belongs to the NSAID class and is primarily used for Moderate to severe rheumatoid arthritis including acute flaresAnkylosing spondylitisOsteoarthritisAcute gouty arthritisPatent ductus arteriosus closure (neonates)Off-label: Pericarditis (prevention of postpericardiotomy syndrome). VIMOVO belongs to the NSAID/PPI Combination class and is primarily used for Relief of signs and symptoms of osteoarthritisRelief of signs and symptoms of rheumatoid arthritisRelief of signs and symptoms of ankylosing spondylitisDecreased risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. INDOMETHACIN SODIUM carries a safety status of Category D/X, whereas VIMOVO safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Esomeprazole is extensively metabolized in the liver primarily by CYP2C19 and CYP3A4. Naproxen is metabolized in the liver primarily by CYP2C9.
Renal (60% as unchanged drug and metabolites, predominantly glucuronide conjugate); fecal (33%, primarily via biliary secretion); <5% unchanged in urine
Renal 50% as naproxen metabolites, <1% unchanged naproxen; less than 1% excreted unchanged in feces as esomeprazole; esomeprazole metabolites excreted in urine 80% and feces 20%.
99% bound to albumin
Naproxen: >99% bound to albumin; esomeprazole: 97% bound to plasma proteins (mainly albumin).
0.34–0.72 L/kg (suggesting extensive tissue distribution, particularly to inflamed sites)
Naproxen: 0.16 L/kg (indicates distribution mainly in plasma and extracellular fluid); esomeprazole: 0.22 L/kg (distribution slightly larger, but still limited).
Oral: 98% (immediate-release); 80–90% (sustained-release). Ophthalmic: negligible systemic absorption
VIMOVO: fixed-dose combination; naproxen bioavailability ~95% (oral); esomeprazole ~64% after oral administration (first-pass metabolism; food delays absorption but does not affect AUC).
Child-Pugh A: No dose adjustment. Child-Pugh B: Reduce initial dose by 50% and titrate cautiously; monitor for toxicity. Child-Pugh C: Contraindicated or avoid use due to risk of hepatic encephalopathy and bleeding.
Child-Pugh A: no adjustment; Child-Pugh B: maximum daily dose naproxen 500 mg; Child-Pugh C: contraindicated.
Intravenous for patent ductus arteriosus: 0.2 mg/kg initially, then 0.1 mg/kg at 12-hour intervals for 3 doses. Oral for juvenile rheumatic conditions: 1.5-3 mg/kg/day in divided doses every 8-12 hours. Maximum daily dose: 4 mg/kg/day (not to exceed 200 mg).
Not recommended for use in pediatric patients.
Initiate at lowest effective dose, starting with 25 mg twice daily oral or IV 0.25-0.5 mg/kg once daily. Titrate slowly. Reduce total daily dose by 50% compared to younger adults. Risk of GI bleeding and renal impairment; monitor closely. Maximum daily dose: 100-150 mg.
Start at lowest effective dose; avoid use in elderly with high bleeding risk; monitor renal function.
Naproxen: Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Naproxen is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk.
Cardiovascular risk (thrombotic events, hypertension), gastrointestinal risk (bleeding, ulceration, perforation), renal toxicity (impaired renal function, nephrotoxicity), hepatic effects (elevated liver enzymes, hepatic failure), hematologic effects (anemia, platelet inhibition), anaphylactoid reactions, exacerbation of asthma, CNS effects (dizziness, headache, depression), ocular effects (corneal deposits, retinal toxicity), premature closure of ductus arteriosus in utero, use in pregnancy (avoid during third trimester due to premature closure).
Hypersensitivity to indomethacin or any NSAID, history of asthma, urticaria, or allergic-type reactions after taking aspirin or NSAIDs, active or recent gastrointestinal bleeding or perforation, perioperative pain in setting of CABG surgery, advanced renal disease, lactation (use with caution), pregnancy (especially third trimester).
Avoid alcohol as it increases risk of GI bleeding and ulceration. No specific food interactions, but taking with food or milk can reduce GI irritation. Maintain adequate hydration to prevent renal toxicity, but avoid excessive salt intake if fluid retention is a concern.
Take on an empty stomach at least 30 minutes before a meal. Avoid alcohol. No specific food restrictions, but high-fat meals may delay absorption.
Indomethacin is excreted into breast milk in low amounts (M/P ratio approximately 0.5-1.0). Relative infant dose is estimated at 1-2% of maternal weight-adjusted dose. Cases of neonatal seizures reported with maternal use. Caution is advised; alternative agents preferred if possible, especially in neonates with thrombocytopenia or renal impairment.
Limited data. Esomeprazole is excreted in human milk in low concentrations (M/P ratio unknown; estimated relative infant dose <1% of maternal weight-adjusted dose). Naproxen enters breast milk in minimal amounts (M/P ratio ~0.01). Due to potential for adverse effects in infants (GI bleeding, renal impairment), use with caution and monitor infant for drowsiness, poor feeding, and rash.
Due to increased volume of distribution and renal clearance in pregnancy, standard dosing may be insufficient; however, NSAIDs are generally avoided in pregnancy. If used, the lowest effective dose for the shortest duration should be employed. No formal dose adjustment guidelines are established; therapeutic drug monitoring is not routine.
No specific pharmacokinetic studies in pregnancy requiring dose adjustments for VIMOVO; however, due to increased plasma volume and renal clearance in pregnancy, naproxen levels may decrease, but dose adjustments are not routinely recommended. Use lowest effective dose for shortest duration, avoid in third trimester.
Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Do not take aspirin or other NSAIDs (e.g., ibuprofen, naproxen) without consulting your doctor.,Report any signs of stomach bleeding (black/tarry stools, vomiting blood) or kidney problems (decreased urination, swelling) immediately.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; do not increase dose or frequency without your doctor's approval.,Store at room temperature away from moisture and heat.
Take VIMOVO on an empty stomach, at least 30 minutes before a meal.,Swallow tablets whole; do not crush, chew, or split.,Do not take with aspirin, other NSAIDs, or anticoagulants unless directed by your doctor.,Report symptoms of stomach bleeding (black/bloody stools, vomiting blood), chest pain, or shortness of breath immediately.,Avoid alcohol and limit salt intake to reduce risk of stomach problems and fluid retention.,Store at room temperature away from moisture and heat.